Market Runner: Could Genetic Technologies Limited (ADR) Decline After Today’s Big Increase?

Market Runner: Could Genetic Technologies Limited (ADR) Decline After Today's Big Increase?

The stock of Genetic Technologies Limited (ADR) (NASDAQ:GENE) is a huge mover today! About 8.02M shares traded hands or 13301.51% up from the average. Genetic Technologies Limited (ADR) (NASDAQ:GENE) has declined 48.83% since April 26, 2016 and is downtrending. It has underperformed by 54.09% the S&P500.
The move comes after 8 months positive chart setup for the $24.56 million company. It was reported on Nov, 29 by We have $2.66 PT which if reached, will make NASDAQ:GENE worth $1.23M more.

According to Zacks Investment Research, “Genetic Technologies was the first company in the world to recognize important new applications for non-coding DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.”

More notable recent Genetic Technologies Limited (ADR) (NASDAQ:GENE) news were published by: which released: “Genetic Technologies Ltd. ADR” on February 13, 2011, also with their article: “DOW JONES, A NEWS CORP COMPANY” published on February 12, 2011, published: “Is Optimism For Genetic Technologies Limited (ADR) (NASDAQ:GENE) Fading?” on February 02, 2015. More interesting news about Genetic Technologies Limited (ADR) (NASDAQ:GENE) were released by: and their article: “Genetic Technologies Limited soars 30%: Here’s why” published on February 13, 2015 as well as‘s news article titled: “Genetic Technologies (GENE) Raises AUD$18.6 Million in Capital” with publication date: March 06, 2015.

GENE Company Profile

Genetic Technologies Limited, incorporated on January 5, 1987, is a molecular diagnostics company. The Firm offers predictive testing and assessment tools to help physicians manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Firm markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment